Data as of May 17
| +0.26 / +1.01%|
The 12 analysts offering 12-month price forecasts for ViroPharma Inc have a median target of 33.00, with a high estimate of 41.00 and a low estimate of 25.00. The median estimate represents a +27.51% increase from the last price of 25.88.
The current consensus among 15 polled investment analysts is to Buy stock in ViroPharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.